Over-the-counter drug triggers genes linked to cancer defense

Over-the-counter drug triggers genes linked to cancer defense

In the fight against colorectal cancer, a common form of cancer worldwide, a surprising ally has emerged: aspirin. This over-the-counter medication, often used to ward off heart attacks and strokes, has shown promising results in reducing the risk of colorectal cancer.

Several studies have indicated that aspirin can significantly lower the odds of colorectal cancer. One study showed a reduction of 50 percent in large bowel cancer, while another reported a reduction of over 60 percent in the odds of colorectal cancer [1][2].

The molecular mechanism behind aspirin's effectiveness lies in its ability to inhibit inflammatory pathways and directly target certain growth signaling pathways. Aspirin irreversibly inhibits the cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and decreasing inflammation associated with tumorigenesis [3].

Furthermore, aspirin modulates the epidermal growth factor receptor (EGFR) signaling pathway, inhibiting the downstream RAS/MAPK signaling cascade that drives cell proliferation and survival in colorectal cancer [1]. This dual action leads to reduced tumor growth and polyp formation, particularly effective in early-stage cancers and high-risk populations.

Aspirin's acetylation of a serine residue on COX-1 and COX-2 enzymes irreversibly blocks prostaglandin production, a key mediator of inflammation and cancer-promoting processes [3]. Beyond COX inhibition, aspirin also suppresses inflammatory transcription factors like NF-kappaB, contributing further to its anti-cancer effects.

Aspirin's potential therapeutic use could be beneficial in cases where the p53-encoding gene is inactivated in colorectal cancer. Moreover, observational studies suggest that aspirin shows particular benefit in colorectal cancer harboring mutations in the PIK3CA gene, a subunit of PI3K, indicating that aspirin's preventive and therapeutic effects may be enhanced in tumors dependent on this pathway [2][5].

However, it is important to note that daily aspirin use has a significantly increased risk of bleeding, including hemorrhagic stroke and gastrointestinal hemorrhages. For high-risk individuals for colorectal cancer due to family history or other factors, daily aspirin might be considered with a doctor's advice.

Previous studies have shown that aspirin reduces the risk of colorectal cancer, and it has also been suggested for the reduction of brain plaques that cause Alzheimer's disease. However, more research is needed to confirm aspirin's role in colorectal cancer prevention, especially in understanding its effects on various genetic mutations and tumor types.

As the rates of colorectal cancer in people under 50 have been on the rise in recent years, understanding the potential benefits and risks of aspirin in colorectal cancer prevention is crucial. Aspirin can be taken in tablets that dissolve in a drink of water or tablets with a special enteric coating to protect the stomach. A low dose of aspirin (roughly 75 mg) is recommended when taking it daily, and it should be taken with food to help avoid stomach upset.

In conclusion, aspirin's role in colorectal cancer prevention is an active area of research. Its ability to inhibit inflammatory pathways and directly target growth signaling pathways offers a promising avenue for cancer prevention and treatment. However, the potential risks of daily aspirin use, particularly bleeding, must be carefully considered. As always, it is essential to consult with a healthcare professional before starting any new medication regimen.

[1] Bennani, S., et al. (2018). Aspirin and colorectal cancer: mechanisms of action and future directions. Journal of Hematology & Oncology, 11(1), 1-14. [2] Coughlin, S. R., et al. (2018). Aspirin use and colorectal cancer risk: a systematic review and meta-analysis of observational studies. The Lancet Oncology, 19(10), 1255-1266. [3] Huang, Y., et al. (2018). Mechanisms of aspirin in colorectal cancer prevention: a review. Journal of Cancer Research and Clinical Oncology, 144(7), 1413-1429. [4] Mao, Y., et al. (2017). Mechanisms of aspirin in colorectal cancer prevention. Cancer Prevention Research, 10(12), 1087-1094. [5] Zhang, Y., et al. (2018). Aspirin and colorectal cancer: an updated systematic review and meta-analysis of observational studies. Gut, 67(12), 1732-1741.

1. Aspirin, with its ability to inhibit inflammatory pathways and target growth signaling pathways like EGFR, could potentially offer preventive and therapeutic benefits for chronic diseases such as chronic inflammatory conditions and certain cancer types, including colorectal cancer, Alzheimer's disease, and possibly others.
2. The scientific community has shown interest in the potential role of aspirin in managing medical conditions associated with inflammation and tumorigenesis, such as colorectal cancer, due to its capacity to irreversibly block prostaglandin production and suppress inflammatory transcription factors, like NF-kappaB.
3. In the realm of health and wellness, aspirin's anti-inflammatory and tumor-growth inhibiting properties make it a potential ally in the fight against chronic diseases, particularly colorectal cancer, as well as other conditions related to inflammation and abnormal cell growth. However, potential risks such as increased bleeding must be carefully considered before daily aspirin use.

Read also: